Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells

Kenji Chamoto, Takemasa Tsuji, Hiromi Funamoto, Akemi Kosaka, Junko Matsuzaki, Takeshi Sato, Hiroyuki Abe, Keishi Fujio, Kazuhiko Yamamoto, Toshio Kitamura, Tsuguhide Takeshima, Yuji Togashi, Takashi Nishimura

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Adoptive immunotherapy using antigen-specific T-helper type 1 (Th1) cells has been considered as a potential strategy for tumor immunotherapy. However, its application to tumor immunotherapy has been hampered by difficulties in expanding tumor-specific Th1 cells from tumor-bearing hosts. Here, we have developed an efficient protocol for preparing mouse antigen-specific Th1 cells from nonspecifically activated Th cells after retroviral transfer of T-cell receptor (TCR)-α and TCR-β genes. We demonstrate that Th1 cells transduced with the TCR-β and -β genes from the I-A d-restricted ovalbumin (OVA)323-339-specific T-cell clone DO11.10 produce IFN-γ but not interleukin-4 in response to stimulation with OVA323-339 peptides or A20 B lymphoma (A20-OVA) cells expressing OVA as a model tumor antigen. TCR-transduced Th1 cells also exhibited cytotoxicity against tumor cells in an antigen-specific manner. Moreover, adoptive transfer of TCR-transduced Th1 cells, but not mock-transduced Th1 cells, exhibited potent antitumor activity in vivo and, when combined with cyclophosphamide treatment, completely eradicated established tumor masses. Thus, TCR-transduced Th1 cells are a promising alternative for the development of effective adoptive immunotherapies.

Original languageEnglish (US)
Pages (from-to)386-390
Number of pages5
JournalCancer Research
Volume64
Issue number1
DOIs
StatePublished - Jan 1 2004

Fingerprint

Adoptive Immunotherapy
T-Cell Receptor Genes
Th1 Cells
T-Cell Antigen Receptor
Neoplasms
Ovalbumin
Antigens
Immunotherapy
Adoptive Transfer
Neoplasm Antigens
Interleukin-4
Cyclophosphamide
Lymphoma
Clone Cells
T-Lymphocytes
Peptides

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chamoto, K., Tsuji, T., Funamoto, H., Kosaka, A., Matsuzaki, J., Sato, T., ... Nishimura, T. (2004). Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells. Cancer Research, 64(1), 386-390. https://doi.org/10.1158/0008-5472.CAN-03-2596

Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells. / Chamoto, Kenji; Tsuji, Takemasa; Funamoto, Hiromi; Kosaka, Akemi; Matsuzaki, Junko; Sato, Takeshi; Abe, Hiroyuki; Fujio, Keishi; Yamamoto, Kazuhiko; Kitamura, Toshio; Takeshima, Tsuguhide; Togashi, Yuji; Nishimura, Takashi.

In: Cancer Research, Vol. 64, No. 1, 01.01.2004, p. 386-390.

Research output: Contribution to journalArticle

Chamoto, K, Tsuji, T, Funamoto, H, Kosaka, A, Matsuzaki, J, Sato, T, Abe, H, Fujio, K, Yamamoto, K, Kitamura, T, Takeshima, T, Togashi, Y & Nishimura, T 2004, 'Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells', Cancer Research, vol. 64, no. 1, pp. 386-390. https://doi.org/10.1158/0008-5472.CAN-03-2596
Chamoto, Kenji ; Tsuji, Takemasa ; Funamoto, Hiromi ; Kosaka, Akemi ; Matsuzaki, Junko ; Sato, Takeshi ; Abe, Hiroyuki ; Fujio, Keishi ; Yamamoto, Kazuhiko ; Kitamura, Toshio ; Takeshima, Tsuguhide ; Togashi, Yuji ; Nishimura, Takashi. / Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells. In: Cancer Research. 2004 ; Vol. 64, No. 1. pp. 386-390.
@article{7c7c0d752b8d47889faa752f7ac2663a,
title = "Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells",
abstract = "Adoptive immunotherapy using antigen-specific T-helper type 1 (Th1) cells has been considered as a potential strategy for tumor immunotherapy. However, its application to tumor immunotherapy has been hampered by difficulties in expanding tumor-specific Th1 cells from tumor-bearing hosts. Here, we have developed an efficient protocol for preparing mouse antigen-specific Th1 cells from nonspecifically activated Th cells after retroviral transfer of T-cell receptor (TCR)-α and TCR-β genes. We demonstrate that Th1 cells transduced with the TCR-β and -β genes from the I-A d-restricted ovalbumin (OVA)323-339-specific T-cell clone DO11.10 produce IFN-γ but not interleukin-4 in response to stimulation with OVA323-339 peptides or A20 B lymphoma (A20-OVA) cells expressing OVA as a model tumor antigen. TCR-transduced Th1 cells also exhibited cytotoxicity against tumor cells in an antigen-specific manner. Moreover, adoptive transfer of TCR-transduced Th1 cells, but not mock-transduced Th1 cells, exhibited potent antitumor activity in vivo and, when combined with cyclophosphamide treatment, completely eradicated established tumor masses. Thus, TCR-transduced Th1 cells are a promising alternative for the development of effective adoptive immunotherapies.",
author = "Kenji Chamoto and Takemasa Tsuji and Hiromi Funamoto and Akemi Kosaka and Junko Matsuzaki and Takeshi Sato and Hiroyuki Abe and Keishi Fujio and Kazuhiko Yamamoto and Toshio Kitamura and Tsuguhide Takeshima and Yuji Togashi and Takashi Nishimura",
year = "2004",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-03-2596",
language = "English (US)",
volume = "64",
pages = "386--390",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells

AU - Chamoto, Kenji

AU - Tsuji, Takemasa

AU - Funamoto, Hiromi

AU - Kosaka, Akemi

AU - Matsuzaki, Junko

AU - Sato, Takeshi

AU - Abe, Hiroyuki

AU - Fujio, Keishi

AU - Yamamoto, Kazuhiko

AU - Kitamura, Toshio

AU - Takeshima, Tsuguhide

AU - Togashi, Yuji

AU - Nishimura, Takashi

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Adoptive immunotherapy using antigen-specific T-helper type 1 (Th1) cells has been considered as a potential strategy for tumor immunotherapy. However, its application to tumor immunotherapy has been hampered by difficulties in expanding tumor-specific Th1 cells from tumor-bearing hosts. Here, we have developed an efficient protocol for preparing mouse antigen-specific Th1 cells from nonspecifically activated Th cells after retroviral transfer of T-cell receptor (TCR)-α and TCR-β genes. We demonstrate that Th1 cells transduced with the TCR-β and -β genes from the I-A d-restricted ovalbumin (OVA)323-339-specific T-cell clone DO11.10 produce IFN-γ but not interleukin-4 in response to stimulation with OVA323-339 peptides or A20 B lymphoma (A20-OVA) cells expressing OVA as a model tumor antigen. TCR-transduced Th1 cells also exhibited cytotoxicity against tumor cells in an antigen-specific manner. Moreover, adoptive transfer of TCR-transduced Th1 cells, but not mock-transduced Th1 cells, exhibited potent antitumor activity in vivo and, when combined with cyclophosphamide treatment, completely eradicated established tumor masses. Thus, TCR-transduced Th1 cells are a promising alternative for the development of effective adoptive immunotherapies.

AB - Adoptive immunotherapy using antigen-specific T-helper type 1 (Th1) cells has been considered as a potential strategy for tumor immunotherapy. However, its application to tumor immunotherapy has been hampered by difficulties in expanding tumor-specific Th1 cells from tumor-bearing hosts. Here, we have developed an efficient protocol for preparing mouse antigen-specific Th1 cells from nonspecifically activated Th cells after retroviral transfer of T-cell receptor (TCR)-α and TCR-β genes. We demonstrate that Th1 cells transduced with the TCR-β and -β genes from the I-A d-restricted ovalbumin (OVA)323-339-specific T-cell clone DO11.10 produce IFN-γ but not interleukin-4 in response to stimulation with OVA323-339 peptides or A20 B lymphoma (A20-OVA) cells expressing OVA as a model tumor antigen. TCR-transduced Th1 cells also exhibited cytotoxicity against tumor cells in an antigen-specific manner. Moreover, adoptive transfer of TCR-transduced Th1 cells, but not mock-transduced Th1 cells, exhibited potent antitumor activity in vivo and, when combined with cyclophosphamide treatment, completely eradicated established tumor masses. Thus, TCR-transduced Th1 cells are a promising alternative for the development of effective adoptive immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=9144239842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144239842&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-2596

DO - 10.1158/0008-5472.CAN-03-2596

M3 - Article

C2 - 14729649

AN - SCOPUS:9144239842

VL - 64

SP - 386

EP - 390

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -